The Latin American Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Latin American Examiner.

Press releases published on September 3, 2026

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arvinas to Participate in Upcoming Investor Conferences
Curia feiert Erweiterung seines Standorts in Albuquerque
Curia celebra la ampliación de sus instalaciones en Albuquerque con una ceremonia de inauguración con corte de cinta
Curia célèbre l’agrandissement de son site d’Albuquerque lors d’une cérémonie d’inauguration
קוריה מציינת את הרחבת המתקן שלה באלבקרקי בטקס גזירת סרט
Curia Merayakan Perluasan Fasilitas di Albuquerque dengan Upacara Pengguntingan Pita
Curia, 리본 커팅 행사 개최하며 앨버커키 시설 확장 기념
Curia Meraikan Pengembangan Kemudahan Albuquerque dengan Majlis Pemotongan Reben
Curia Celebra Expansão das Instalações de Albuquerque com Cerimônia de Corte de Fita
Curia เฉลิมฉลองการขยายโรงงานในเมืองแอลบูเคอร์คีด้วยพิธีตัดริบบิ้น
Curia 為阿爾伯克基廠房擴建舉行剪綵儀式
キュリア、アルバカーキ施設の拡張を記念してテープカット式典を開催
Curia举办剪彩仪式,庆祝阿尔伯克基工厂扩建落成
Curia Celebrates Expansion of Albuquerque Facility with Ribbon-Cutting Ceremony
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease
Five Stone Slab Cutting Machine Manufacturers Reviewed: Multi-Wire Saw Machines and One-Stop Stone Processing Solutions
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Latin American Examiner

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.